Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21299895 | 1.00 | PRMT5 (0.70) | PRMT5WDR77 | |
| SCHEMBL21137848 | 0.94 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL16217502 | 0.94 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL21299849 | 0.89 | PRMT5 (0.68) | PRMT5WDR77 | |
| SCHEMBL15944110 | 0.89 | PRMT5 (0.68) | PRMT5WDR77 | |
| SCHEMBL21139764 | 0.84 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL16217546 | 0.84 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL16217538 | 0.84 | PRMT5 (0.78) | PRMT5WDR77 | |
| SCHEMBL21140473 | 0.84 | PRMT5 (0.78) | PRMT5WDR77 | |
| SCHEMBL15944725 | 0.83 | PRMT5 (0.78) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9732072-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732072-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2016089883-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-20160137631-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137631-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885 |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885 |
| US-20160137631-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.